The FDA is aggressively integrating artificial intelligence to streamline and expedite its drug review processes. Under Commissioner Martin Makary’s leadership, the agency unveiled plans featuring an AI document evaluation tool, aiming for rapid or near-instant assessment of regulatory submissions. This initiative reflects a broader commitment to harness technological innovation to address increasing drug approvals demands, especially following workforce reductions. The strategic AI deployment seeks to enhance efficiency while maintaining rigorous scientific standards.